Assess the Safety of a Microneedle Patch for Vaccination Against Rotavirus When Given Intradermally for Four (4) Administrations in Rats
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
CDC OFFICE OF ACQUISITION SERVICES
Contract Value
Not provided
Codes & Classification
Solicitation Number
CDC-75D301-Presolicitation-SMNVARRATS
NAICS
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Classification Code
B599
Additional Details
The Centers for Disease Control and Prevention (CDC), through its National Center for Immunizations and Respiratory Diseases (NCIRD), has issued a Special Notice indicating its intent to award a sole source, firm fixed price contract to Southern Research Institute, located at 2000 9th Avenue S, Birmingham, Alabama. This procurement is not open for competitive quotes, as it is being conducted under the authority of FAR 13.106-1(b)(1)(i) and 10 U.S.C. 2304(c)(1), which allows for sole source awards when only one responsible source is capable of meeting the agency’s requirements.
The primary objective of this contract is to assess the safety of a Live Attenuated Rotavirus Vaccine (LARV) delivered via a microneedle (MN) patch, specifically when administered intradermally in rats across four separate administrations. This preclinical safety evaluation is to be conducted in accordance with applicable regulatory requirements, supporting the CDC’s ongoing efforts to advance innovative vaccination technologies and improve immunization strategies against rotavirus.
The period of performance for this contract is scheduled from May 15, 2026, through May 14, 2028. The work will be performed in Atlanta, Georgia. The applicable North American Industry Classification System (NAICS) code is 541715, which covers Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). The Product Service Code (PSC) associated with this requirement is B599.
While this notice is not a solicitation for competitive proposals, the CDC invites interested parties to submit capability statements. These statements must provide detailed management and technical data, as well as cost information, to convincingly demonstrate the ability to meet the CDC’s requirements for this specialized research. Capability statements are limited to two pages (8.5 x 11 inches, minimum 10-point font) and must be submitted electronically in Microsoft Word or Adobe PDF format. The deadline for submission is 10:00 AM Eastern Standard Time on April 9, 2026. Submissions should be sent via email to Tim Williams at [email protected]; telephone inquiries will not be accepted.
The CDC Office of Acquisition Services is the contracting entity for this procurement, operating under the Department of Health and Human Services. The notice remains active and can be referenced on SAM.gov under Opportunity ID 9b6a434ab6bf4045a42a583cd4673050.
Contractors considering this opportunity should note that the CDC is seeking highly specialized expertise in preclinical vaccine safety assessment, particularly with experience in microneedle patch technologies and animal model studies. The sole source determination is based on the unique capabilities required to fulfill the agency’s research objectives. All information received in response to this notice will be used solely to determine whether a competitive procurement process is warranted.
For further information or to submit a capability statement, interested parties should contact Tim Williams at [email protected] or 770-488-2791.